摘要
目的:研究谷胱甘肽硫转移酶(GSTs)基因多态性与环磷酰胺在难治性肾病综合征的不良反应关系。方法:运用等位基因特异性PCR(ASPCR)和PCR-限制性片段长度多态性(PCR-RFLP)的方法分析谷胱甘肽硫转移酶基因型;参照SFDA的不良反应分析标准分析环磷酰胺在难治性肾病综合征的不良反应。结果:骨髓抑制组和胃肠道反应组含有GSTP1(I/V或V/V)的机率高于无骨髓抑制组和无胃肠道反应组,GSTP1(I/V或V/V)组患者发生骨髓抑制和胃肠道反应机率高于GSTP1(I/I)组患者。结论:环磷酰胺治疗前检测GSTs基因多态性有助于避免骨髓抑制和胃肠道反应的发生。
OBJECTIVE To study the relation of glutathione S-transferase genotype with the adverse drug reaction of cyclophosphamide in nephritic syndrome patients. METHODS Glutathione S-transferase polymorphisms were analyzed by ASPCR and the PCR-RFLP method, Refractory nephrotic syndrome adverse reactions of cyclophosphamide were analyzed using SFDA ADR criteria. RESULTS The frequency of gastrointestinal reactions containing GSTP1 （I/V or V/V） of marrow suppression is higher than those without gastrointestinal tract Reaction Group and without marrow suppression group（I/V or V/V）. The frequency of marrow suppression and gastric intestinal reaction of GSTP1 （I/V or V/V）group is higher than GSTP1 （I/I） group. CONCLUSION Patients with mutation alleles of GSTP1 are likely to have bone marrow suppression and gastrointestinal reactions. To detect the glutathione S-transferase genotype before using cyclophosphamide is significant to improve the therapeutic safety.
出处
《中国医院药学杂志》
CAS
CSCD
北大核心
2009年第2期99-103,共5页
Chinese Journal of Hospital Pharmacy
基金
国家自然科学基金(编号:30571975)
深圳市科技计划基金(编号:200702143)
关键词
谷胱甘肽硫转移酶
环磷酰胺
不良反应
Glutathione S-transferase
cyclophosphamide
adverse drug reaction
